Literature DB >> 3943388

Staging of non-small cell bronchogenic carcinoma. Relationship of the clinical evaluation to organ scans.

D L Quinn, L B Ostrow, D K Porter, D K Shelton, D E Jackson.   

Abstract

Organ scans are generally performed on patients with bronchogenic carcinoma only when clinical evaluation is suspicious for metastases. However, it is not clear whether the clinical abnormalities will direct attention to the single organ which should be scanned, or if all three organs (bone, brain, liver) should be evaluated if any clinical abnormality is present. We investigated the use of triple organ radionuclide scanning and computerized tomography (CT) of the brain in the initial staging of patients with non-small cell bronchogenic carcinoma with no obvious metastases. Of 122 patients with newly diagnosed lung cancer, 53 met our criteria for further study. Thirty-three (62 percent) of these had at least one clinical abnormality suggestive of metastasis. Bone scanning detected metastases in seven (21 percent) and head CT in two additional patients (6 percent). Brain and liver scanning had no yield. In only five of these nine patients did the clinical abnormality direct attention to the organ with detectable metastases. Twenty of the 53 (38 percent) patients had a negative routine clinical evaluation, yet bone scanning showed metastases in three (15 percent). We concluded that clinical abnormalities are not specific for the organ in which metastases may be detected, so three scans (bone, liver, CT of the brain) should be obtained if there is any suspicion of metastasis based on history, physical examination, and laboratory tests. The value of bone scanning in clinically normal patients deserves further study.

Entities:  

Mesh:

Year:  1986        PMID: 3943388     DOI: 10.1378/chest.89.2.270

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

Review 1.  Staging for M disease.

Authors:  T L Winton
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

2.  Preoperative screening for metastases in lung cancer.

Authors:  M F Muers
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

3.  Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning.

Authors:  F Michel; M Solèr; E Imhof; A P Perruchoud
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

Review 4.  Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer.

Authors:  T K Hillers; M D Sauve; G H Guyatt
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

5.  Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  David E Ost; Sai-Ching Jim Yeung; Lynn T Tanoue; Michael K Gould
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

6.  In vivo molecular targeted radiotherapy.

Authors:  Ac Perkins
Journal:  Biomed Imaging Interv J       Date:  2005-10-01

7.  Can clinical factors be determinants of bone metastases in non-small cell lung cancer?

Authors:  Ahmet Ursavas; Mehmet Karadag; Esra Uzaslan; Erkan Rodoplu; Ezgi Demirdögen; Basak Burgazlioglu; R Oktay Gozu
Journal:  Ann Thorac Med       Date:  2007-01       Impact factor: 2.219

8.  Is there any significance of lung cancer histology to compare the diagnostic accuracies of (18)F-FDG-PET/CT and (99m)Tc-MDP BS for the detection of bone metastases in advanced NSCLC?

Authors:  Ali Inal; Muhammed Ali Kaplan; Mehmet Kucukoner; Zuhat Urakcı; Zeki Dostbil; Hail Komek; Hakan Onder; Bekir Tasdemir; Abdurrahman Isıkdogan
Journal:  Contemp Oncol (Pozn)       Date:  2014-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.